# Univariate and Multivariate data analysis

Set the scene Talk about design and analysis Biomarker or perturbation experiments Roy Goodacre School of Chemistry and MIB University of Manchester

# Mega- & Multivariate data

A sample resides somewhere in 2D or 3D space But if one collects 100 variables… Need to visualise 100 D space! underlying theme of multivariate analysis (MVA) is thus *simplification* or *dimensionality* reduction 0 0 500 Chlorogenic acid 1500 0 2000 t t n GB U. N GB <sup>N</sup> L N K LN K k F F gbi  $\mathbf{h}_{\mathsf{g}\mathsf{b}}$ 



2000

Caffiene

### Data floods

Pairs:

Identifier: transcript / protein / metabolite Quant Info: concentration or ratio

ACKOUT

BL.

# Defence against data floods

www.cis.nctu.edu.tw

Experimental design Data collection Databases of Metadata and Data Data pre-processing Data analysis Data interpretation

### Is this a good experimental design?

- ◆ Liver failure from plasma
- ◆ Metabolome measured with GC-MS & LC-MS

**Table 1.** Demographic Information of the Healthy Group and Liver Failure Patient Group Investigated<sup>a</sup>

	healthy group $(n = 23)$	patient group $(n = 24)$
Gender (male/female)	15/8	21/3
<b>HBsAg</b>	Negative	Positive
Age (year)	$27.39 \pm 9.24$	$46.77 \pm 13.35$
ALT (U/L)	~140	$172.63 \pm 147.49$
$TB \ (umol/L)$	12	$457.33 \pm 135.48$
PT(s)	14	$26.06 \pm 15.14$
MELD score		$24.68 \pm 8.38$

<sup>a</sup> Abbreviations: ALT, alanine aminotransferase; TB, total bilirubin; PT, prothrombin time; MELD, model for end-stage liver disease. The value is represented as the form of mean  $\pm$  SD.

#### Lawton, K.A. (2008) *Pharmacogenomics* **9**, 383-397

## Is this a good experimental design?

- 27) acute lymphoblastic leukemia
- (11) acute myeloid leukemia

#### **Childhood**

Adult

Affymetrix arrays with 6,817 probes



Golub *et al*. (1999) *Science* **286**, 531-537

### Sample size bias

◆ Should try to have even cohort sizes

◆ Using a large sample size does not directly address bias, although it can reduce statistical uncertainty by providing a smaller confidence interval around a result.

### Is this a good experimental design?

◆ Pre-eclampsia: Pregnancy-induced hypertension

Metabolomics: GC-MS of serum Measuring BP?



Demographic data for patients from whom plasma samples were taken

Median (range). Pre-eclampsia vs normal outcome.

 $*_p$  < 0.0001.



#### Markers found did not correlate with BP



# Ronald A. Fisher (1938)



"To call in the statistician after the experiment is done may be no more than asking him to perform a post-mortem examination: he may be able to say what the experiment died of"

> \*Broadhurst, D. & Kell, D.B. (2006) *Metabolomics* **2**, 171-196 \* and this is why most claimed research findings are false

## Statistician needed at onset



Was randomisation successful: Check!

In case-control studies only non-random thing should be what you are testing for

**Nature Reviews | Cancer** 

Ransohoff, D.R. (2005) *Nature Reviews Cancer* **5**, 142-149

# All about **Null hypothesis (H<sup>0</sup> )**

- Given the test scores of two random samples of guilty people and innocent people, does one group differ from the other?
- $\blacklozenge$  A possible null hypothesis is that the mean score for guilty is the same as the mean innocent score. In other words  $H_0: \mu_1 = \mu_2$



 Type I error can be thought of as "convicting an innocent person" Type II error "letting a guilty person go free"

# Data handling



## Unsupervised methods

### ◆ Use X data only

 $\&$  X data = transcript/protein/metabolite levels

 $\psi$  Inputs to some analysis method

### ◆ Most common methods

- $\psi$  Principal components analysis (PCA)
- **♦ Clustering methods**
- $\mathfrak{B}$  Kohonen neural networks

# Uncovering correlations in data

◆ Correlations between *x* variables are confusing. Need to examine the *structure* within data sets, rather than using them blindly. ◆ Finding such structure by hand can be extremely difficult, even in relatively simple

cases.

#### **use projections**

# Who's there?

- $\blacklozenge$  Data  $\rightarrow$  random mess?
- ◆ On rotation of the data …

![](_page_14_Figure_3.jpeg)

# Projection of the data

![](_page_15_Figure_1.jpeg)

# Principal components analysis

#### ◆ Finds structure in such data sets.

- ◆ An old method
	- $\rightarrow$  Karl Pearson (1901)  $\rightarrow$  Hotelling (1933)
- ◆ Rotate to uncover *maximum* correlations
- First axis placed along the most *natural variation*
- ◆ Second axis orthogonal to this to find 2<sup>nd</sup> highest correlation, and so on
- $\blacklozenge$  Plot axes  $\rightarrow$  spot major underlying structures automatically

![](_page_17_Figure_0.jpeg)

![](_page_17_Figure_1.jpeg)

 $PC1 = 1$ <sup>st</sup> principal component describes largest variance goes through variable origin space  $t_{j1}$  = score for point j = distance from projection of that point onto PC1 from origin

 $PC2 = 2<sup>nd</sup> principal component$  describes 2nd largest variance goes through variable origin space  $t_{j2}$  = score for point j

# Who's there?

- $\rightarrow$  Data  $\rightarrow$  random mess?
- ◆ On rotation of the data …
- ◆ Uncovered where variance and correlations are

150 100 Next most variance Next most variance 50  $\boldsymbol{\Theta}$  $-50$  $-100$ 

Ø

50

100.

150

 $-150$ 

 $-150 - 100 - 50$ 

Maximu<sup>p</sup>nCyariance

![](_page_19_Figure_0.jpeg)

http://www.airnav.com/airport/0

![](_page_20_Figure_0.jpeg)

\ **PCA removes 'noise'**

### PCA scores plot

![](_page_21_Figure_1.jpeg)

# European employment data, 1979

#### ◆26 European countries

◆9 variables for each

 $\mathbb Q$  agriculture, mining, manufacturing, power supplies, construction, service industries, finance, social and personal services, transport and communications

### ◆ PC1 and PC2

 $\triangle$  account for 67.3% of total variance

![](_page_23_Figure_0.jpeg)

### Predictive analyses

![](_page_24_Figure_1.jpeg)

**Input data Output data**

# Supervised learning methods

### ◆ Use X and Y data

 $\&$  X data are mRNA/protein/metabolite levels as Inputs  $\forall Y$  data are targets as Outputs

#### ◆ Analysis can be:

**W** Univariate

 $\mathfrak{B}$  Multivariate

**Wust be validated** 

# Univariate testing methods

![](_page_26_Picture_105.jpeg)

Tests comparing means known as parametric test, more powerful but lest adaptive. Tests comparing medians known as non-parametric, less powerful but more adaptive.

Thanks to Dr Yun Xu

## Extended to multivariate data

◆ For each measurement perform a test.

Null hypothesis is that the mean metabolite level for the diseased cohort is the same as the mean for the healthy control group

![](_page_27_Picture_74.jpeg)

![](_page_28_Figure_0.jpeg)

![](_page_28_Figure_1.jpeg)

Broadhurst, D. & Kell, D.B. (2006) *Metabolomics* **2**, 171-196

# Multivariate analysis methods

◆ Most common methods  $\mathfrak{S}$  (Fisher or PLS) discriminant analysis  $\&$  **Partial least squares (PLS) regression** 

◆ Outputs

 $\frac{1}{2}$  Scores plots

 $\mathfrak{S}$  Target outputs or 'labels'  $\rightarrow$  Identification

◆ Projection based

 $\frac{1}{2}$  Just like PCA but this time with respect to some label (from the Y data)

Discriminant function analysis (aka, canonical variates analysis)

- Uses uncorrelated inputs *a priori* information
- ◆ Projection based on:
	- $\psi$  Minimises within group variance
	- $\mathfrak{B}$  Maximises between group variance
- ◆ Test by projection of

![](_page_30_Picture_7.jpeg)

# Peat

- 6 groups
- $Circles = 95%$  $\chi^2$  confidence limits
- Arrows represent outlier samples that were from upper horizon of the peat depth profile

![](_page_31_Figure_4.jpeg)

Harrison, B. *et al*.. (2006) *Journal of the Institute of Brewing* **112**, 333-339.

## Target Output for PLS

◆ Usually binary encoded:

Known diseases

![](_page_32_Picture_66.jpeg)

Easy look up table

## Target Output for PLS

#### ◆ Can be quantitative:

Level of disease; e.g., Gleason Grades

![](_page_33_Picture_64.jpeg)

# Supervised methods are powerful…

- ◆ Learn from experience
- ◆ Generalise from previous examples to new ones
- ◆ Perform pattern recognition on complex multivariate data.
- ◆ Make errors
	- $\mathfrak{B}$  usually because of badly chosen data
	- $\mathfrak{B}$  tanks from trees...

#### **Use validation**

# Validation uses data resampling

#### ◆ Resampling methods

- $\frac{1}{2}$  Training set and a Monitoring set
- $\frac{1}{2}$  Select subsets from the training data, while keeping the training pairs together

#### ◆ External validation

 $\&$  Do the experiment again with a different cohort

Goodacre R. *et al*. (2007) *Metabolomics* **3**, 231-241

# Resampling approaches

#### ◆ Leave-one-out validation (LOO)

Single training pair (X-data and Y-data) left out and rest used for training

 $\&$  Repeat until all samples have been left out once

#### ◆ K-fold validation

 $\frac{1}{2}$  Split data into slices:

- $\Rightarrow$  one slice monitors the model
- $\Rightarrow$  remainder used as the training set

# Better still

### ◆ Bootstrapping

 $\%$  On average' 36.8% samples were used for testing and 63.2% samples for training

 $\&$  Do many times (say 1000)

 $\&$  Do statistics on test data only

◆ Permutation testing

 $\&$  Null distribution using lots of permutation tests ↓ Use same data but answer (Y-data) is permuted

### Biomarker Discovery: From lab to bedside

 $\begin{pmatrix} 1 \\ 1 \end{pmatrix}$ **Increasing** sample numbers and throughput **To the clinic**

**Representative Cohort study (***n***=1000s) with analysis of candidates (LC-MS and/or assay)**

**Set of candidate things to measure**

**Hypothesis validation (independent sample set 2)**

**Hypothesis generation study 1 (independent sample set 1)**

**Conception (objectives, collaborations, design of experiment)**

# Data rich environment needs statistical analyses

![](_page_39_Picture_1.jpeg)

"Statistics are like bikinis. What they reveal is suggestive, but what they conceal is vital" Aaron Levenstein

![](_page_39_Picture_3.jpeg)

"All models are wrong, but some are useful" George E. P. Box

### Biomarker Discovery: From lab to bedside

**Biological Understanding**

**To the clinic**

**Representative Cohort study (***n***=1000s) with analysis of candidates (LC-MS and/or assay)**

**Set of candidate metabolites**

**Hypothesis validation (independent sample set 2)**

**Hypothesis generation study 1 (independent sample set 1)**

**Conception (objectives, collaborations, design of experiment)**

**Increasing** sample numbers and throughput

 $\begin{pmatrix} 1 & 1 \\ 1 & 1 \end{pmatrix}$